Skip to main content

Visit our other sites

jnj.com
jnjinnovation network
Quickfire Challenges

Main navigation

Home
About us
Partner with us
Blog
News
Challenges
Video hub
Connect with Us

News

Maintabs

All news
Press releases
In the media
Partner news
Social
Other News

Article view
List view

Refine by

Refine by

Type

In the media
(-) JNJ Press releases
(-) Partner news

Period

2022
2021
2020
2019
(-) 2018
2017
2016
2015
2014
2013
2012
2010
2009

Jan
Feb
Mar
(-) Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

Locations & regions

Focus area

Clear filters

News

Joint Purification Systems, Inc. Announces $7.8 Million Series A Financing

Read full story

ViaCyte Substantially Expands Patent Portfolio in Stem Cell-Derived Cell Replacement Therapies for Type 1 Diabetes and Other Indications

Read full story

ViaCyte Awarded NIH SBIR Grant to Support In Vitro Development of Stem Cell-Derived Functional Human Pancreatic Beta Cells

Read full story

JNJ Press releases

Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases

Read full story

RefleXion Medical Raises $100 Million Series C to Commercialize Revolutionary Cancer Treatment

Read full story

Sidebar

Currently trending

Currently trending

Locus Biosciences Announces $35 Million Financing
VantAI Announces Multi-Year Protein Degrader Discovery Collaboration with Janssen
Bioasis Enters Into Research Collaboration With Janssen
Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors
Biocom conference charts prospects for life sciences industry amid stock market volatility
Remix Therapeutics Enters Collaboration with Janssen to Advance Small Molecule Therapeutics Using REMaster Drug Discovery Platform to Modulate RNA Processing
VerImmune Inc Announces Research Collaboration with Janssen to Leverage its Unique Immuno-oncology Therapeutic Platform
Mersana Therapeutics Announces Research Collaboration and License Agreement with Janssen to Advance Novel Antibody-Drug Conjugates
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
Navitor Pharmaceuticals Announces Janssen Has Acquired Anakuria Therapeutics, Inc.

Trending

Trending

A JLABS Collaboration: DC4U

A JLABS Collaboration: Neurocast

Johnson & Johnson Innovation: Our Partnership Story